EP
CYAD

Eversept Partners’s Celyad Oncology SA American Depositary Shares CYAD Stock Holding History

Eversept Partners’s Portfolio CYAD Stock Details CYAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-12,840
Closed -$382K – 77
2018
Q2 		$382K Buy
+12,840
New +$394K 0.17% 65

Other funds holding CYAD

Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
Zurich Cantonal Bank
Zurich Cantonal Bank Zurich, Switzerland $46B AUM 27.59% 1-Year Est. Return

Eversept Partners's CYAD Position: Q3 2018 in Review

Eversept Partners sold out of Celyad Oncology SA American Depositary Shares (CYAD) in Q3 2018, closing a stake of 12,840 shares — an estimated $382K sold.

Eversept Partners first reported a position in CYAD in Q2 2018 and held it in 1 quarter. The position peaked at $382K in Q2 2018. 12 funds tracked by Wall St. Rank hold CYAD as of Q3 2018.

  • Eversept Partners reported no remaining Celyad Oncology SA American Depositary Shares position as of Q3 2018 after selling out during the quarter.
  • Eversept Partners sold 12,840 Celyad Oncology SA American Depositary Shares shares in Q3 2018, an estimated $382K.
  • Eversept Partners first reported a position in Celyad Oncology SA American Depositary Shares in Q2 2018 and held it in 1 quarter.
  • Eversept Partners's Celyad Oncology SA American Depositary Shares position peaked at $382K in Q2 2018.
  • 12 funds tracked by Wall St. Rank held Celyad Oncology SA American Depositary Shares as of Q3 2018.

Based on Eversept Partners's 13F filing for Q3 2018, filed 14 Nov 2018.